1. Home
  2. ASIX vs CTNM Comparison

ASIX vs CTNM Comparison

Compare ASIX & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AdvanSix Inc.

ASIX

AdvanSix Inc.

HOLD

Current Price

$20.22

Market Cap

600.1M

Sector

Industrials

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$15.24

Market Cap

550.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASIX
CTNM
Founded
2016
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
600.1M
550.7M
IPO Year
2016
2024

Fundamental Metrics

Financial Performance
Metric
ASIX
CTNM
Price
$20.22
$15.24
Analyst Decision
Buy
Buy
Analyst Count
2
4
Target Price
$26.00
$19.00
AVG Volume (30 Days)
201.9K
252.5K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
2.62%
N/A
EPS Growth
11.11
0.46
EPS
N/A
N/A
Revenue
$1,684,625,000.00
N/A
Revenue This Year
$4.19
N/A
Revenue Next Year
$4.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
45.49
N/A
52 Week Low
$14.10
$6.19
52 Week High
$26.73
$16.91

Technical Indicators

Market Signals
Indicator
ASIX
CTNM
Relative Strength Index (RSI) 45.81 57.70
Support Level $19.22 $13.23
Resistance Level $20.48 $15.52
Average True Range (ATR) 0.77 1.16
MACD -0.05 0.11
Stochastic Oscillator 26.91 65.12

Price Performance

Historical Comparison
ASIX
CTNM

About ASIX AdvanSix Inc.

AdvanSix Inc is a diversified chemistry company playing a critical role in international supply chains, innovating and delivering essential products for customers across a wide variety of end markets and applications that touch people's lives, including building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, and electronics. The company's key products include Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates. The majority of sales are from Plant Nutrients products. The company operates in the United States and internationally, with the majority of revenue coming from the United States.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: